Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635
暂无分享,去创建一个
H. Wikström | G. Sedvall | C. Halldin | V. Pike | L. Farde | H. Hall | C. Lundkvist | C Halldin | H Hall | L Farde | G Sedvall | A. Fletcher | A Fletcher | C Lundkvist | V. W Pike | J. A McCarron | I. A Cliffe | T Barf | H Wikström | J. A. McCarron | T. Barf | I. Cliffe | I. A. Cliffe
[1] F. Yocca. Neurochemistry and Neurophysiology of Buspirone and Gepirone: Interactions at Presynaptic and Postsynaptic 5‐HT1A Receptors , 1990, Journal of clinical psychopharmacology.
[2] D. Baldwin,et al. The role of serotonin in depression and anxiety , 1995, International clinical psychopharmacology.
[3] B. Långström,et al. In vivo and in vitro receptor autoradiography of the human brain using an 11C-labelled benzodiazepine analogue , 1988, Neuroscience Letters.
[4] G. Sedvall,et al. Autoradiography with saturation experiments of 11C-Ro 15–1788 binding to human brain sections , 1991, Journal of Neuroscience Methods.
[5] Anat Biegon,et al. Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol , 1991, Brain Research.
[6] M. Minchin,et al. Characterisation of the Binding of [3H]WAY‐100635, a Novel 5‐Hydroxytryptamine1A Receptor Antagonist, to Rat Brain , 1995, Journal of neurochemistry.
[7] G. Wooten,et al. Quantitative film autoradiography of opiate agonist and antagonist binding in rat brain. , 1983, The Journal of pharmacology and experimental therapeutics.
[8] H. Wikström,et al. Potential anxiolytic properties of R-(+)-8-OSO2CF3-PAT, a 5-HT 1A receptor agonist. , 1996, European journal of pharmacology.
[9] A A Lammertsma,et al. Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. , 1994, European journal of pharmacology.
[10] X. Khawaja,et al. Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist , 1995, Brain Research.
[11] A. S. Eison,et al. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. , 1986, The American journal of medicine.
[12] G. Sedvall,et al. Carbon-11 labelling of eticlopride in two different positions--a selective high-affinity ligand for the study of dopamine D-2 receptors using PET. , 1990, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.
[13] D. Wright,et al. Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain , 1995, The Journal of comparative neurology.
[14] P R Saxena,et al. Serotonin receptors: subtypes, functional responses and therapeutic relevance. , 1995, Pharmacology & therapeutics.
[15] J. Kleinman,et al. Serotonin Uptake Sites and Serotonin Receptors Are Altered in the Limbic System of Schizophrenics , 1993, Neuropsychopharmacology.
[16] S. Paul,et al. Preclinical Pharmacology of Buspirone Hydrochloride , 1984, Pharmacotherapy.
[17] L. Descarries,et al. Serotonin 5-HT1 and 5-HT2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: a quantitative autoradiographic study , 1993, Brain Research.
[18] M. Hamon,et al. Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. , 1994, European journal of pharmacology.
[19] J. Palacios,et al. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites , 1986, Brain Research.
[20] Christer Halldin,et al. Autoradiographic localization of extrastriatal D2‐dopamine receptors in the human brain using [125I]epidepride , 1996, Synapse.
[21] Christer Halldin,et al. Distribution of D1- and D2-Dopamine Receptors, and Dopamine and Its Metabolites in the Human Brain , 1994, Neuropsychopharmacology.
[22] S. Hjorth,et al. Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? , 1986, European journal of pharmacology.
[23] P. Grasby,et al. Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PET. , 1996, Nuclear medicine and biology.
[24] Allan Fletcher,et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist , 1995, Behavioural Brain Research.
[25] M. Mintun,et al. [11C]WAY 100635: a radioligand for imaging 5-HT1A receptors with positron emission tomography. , 1994, Life sciences.
[26] S. Peroutka,et al. Antagonism of 5-hydroxytryptamine1A (5-HT1A) receptor-mediated modulation of adenylate cyclase activity by pindolol and propranolol isomers. , 1988, Biochemical pharmacology.
[27] Paul J. Harrison,et al. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain , 1995, Brain Research.
[28] I. Martin,et al. Molecular biology of 5-HT receptors , 1994, Neuropharmacology.
[29] J. Palacios,et al. Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors , 1987, Neuroscience.
[30] P A Sargent,et al. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. , 1996, European journal of pharmacology.
[31] J. Glowinski,et al. Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT , 1983, Nature.
[32] I A Cliffe,et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. , 1995, European journal of pharmacology.
[33] A Malizia,et al. First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635. , 1995, European journal of pharmacology.
[34] M. Hamon,et al. The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. , 1995, European journal of pharmacology.
[35] S. Hjorth,et al. 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. , 1981, Journal of medicinal chemistry.
[36] C. Dourish,et al. Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents. , 1993, Trends in pharmacological sciences.
[37] M. Hamon,et al. [3H]8‐Hydroxy‐2‐(Di‐n‐Propylamino)Tetralin Binding to Pre‐ and Postsynaptic 5‐Hydroxytryptamine Sites in Various Regions of the Rat Brain , 1985, Journal of neurochemistry.
[38] L. Farde,et al. Positron emission tomography--examination of chemical transmission in the living human brain. Development of radioligands. , 1992, Arzneimittel-Forschung.
[39] H. Berendsen,et al. Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? , 1995, Pharmacology & therapeutics.
[40] H. Meltzer,et al. Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia , 1996, Brain Research.
[41] S. Watson,et al. Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain — a combined in situ hybridisation/in vitro receptor autoradiographic study , 1991, Brain Research.